HOUSTON, Nov. 16, 2026 (GLOBE NEWSWIRE) — Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”), a commercial-stage medical device company focused on developing and marketing regenerative therapies for chronic wound care, announced financial results for the third quarter ended September 30, 2026 and provided an operational and business update.

Third Quarter and First Nine Months 2026 Financial Summary

  • Total revenues of approximately $1.9 million and $4.9 million for the third quarter 2026 and first nine months of 2026, respectively, increased 80% and 123%, respectively, versus the comparable 2025 periods.
  • Total product revenues in the third quarter increased 5% sequentially versus the second quarter 2026 with Aurix wound care revenues increasing approximately 17% sequentially which is the same average sequential growth rate over the past six quarters for Aurix wound care revenues.
  • Third quarter net operating loss of approximately $374,000 improved by approximately $166,000 compared to third quarter 2025 while increasing approximately $208,000 sequentially versus the second quarter. The sequential increase primarily reflected higher stock-based compensation, credit loss provision expense, and more than $100,000 of elevated regulatory costs associated with component supply matters.
  • Subsequent to quarter end, final funding of $325,000 was received under the loan agreement with total borrowings established at $2,000,000.

Operational and Business Update

  • Received $250,000 reimbursement fee milestone pursuant to the 2025 distribution agreement with Smith+Nephew.
  • Final Medicare OPPS (Outpatient Prospective Payment System) reimbursement ruling recently released for calendar 2027 with the per treatment G0465 national average reimbursement increasing to approximately $2,257 or 7% from 2026 with positive pricing actions for Aurix anticipated next year.
  • Medicare’s PFS (Physician Fee Schedule) ruling established a G0465 national average reimbursement of approximately $1,020 in 2027 or a decrease of approximately 4%.
  • Expansion of coverage and processing of G0465 claims for nursing home treatments (Medicare Place of Service 32) effective January 1, 2027 is expected to be positive for future growth.

“As many wound care market participants have commented, the broader wound care space remains unsettled resulting from the dramatic January change to reimbursement economics for skin substitutes/grafts which remained unchanged in the final 2027 rulings mentioned above,” commented David Jorden, Nuo’s Chief Executive and Financial Officer.  

“We have also observed a shift of patients and wound care volumes back to hospital-based settings and enjoyed our highest quarter ever of Aurix revenues in the hospital setting,” continued Mr. Jorden. “Since this year’s first quarter, our HOPD Aurix sales as a percentage of total wound care sales has more than doubled. The economics in hospital settings are strong, and we will continue to pursue and emphasize growth opportunities in this segment. We remain confident that autologous PRP and Aurix in particular are well positioned for continued long term attractive growth.”

“As a business, we are prioritizing both reaching the revenue level required for operational breakeven and assessing opportunities to strengthen our capital structure to support Nuo’s next stage of growth. The funding of the secured notes under the loan agreement in several tranches this year was done with these priorities in mind,” concluded Mr. Jorden.

About Nuo Therapeutics

Nuo Therapeutics, Inc. is a commercial-stage medical device company focused on developing and marketing regenerative therapies for chronic wound care. Nuo’s Aurix System is a biodynamic hematogel that harnesses a patient’s innate regenerative abilities for the management of a variety of wounds.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements. These forward-looking statements include but are not limited to statements regarding Nuo’s anticipated growth opportunities and market positioning, including in the hospital outpatient setting, expectations regarding Medicare reimbursement and coverage changes, including the expansion of coverage to nursing home treatments, and their impact on demand for and pricing of Aurix, anticipated pricing actions, movement toward breakeven operations, and Nuo’s ability to strengthen its capital structure. Forward-looking statements may include statements that are predictive in nature and depend upon or refer to future events or conditions, and may include words such as “believes,” “plans,” “anticipates,” “projects,” “estimates,” “expects,” “intends,” “strategy,” “future,” “opportunity,” “may,” “will,” “should,” “could,” “potential,” or similar expressions. You are cautioned not to unduly rely on forward-looking statements. Forward-looking statements are based on current expectations, assumptions, and information available to Nuo’s management and are subject to known and unknown risks, uncertainties and other factors which may cause actual results to differ materially from the forward-looking statements. These risks, uncertainties, and factors are discussed under “Risk Factors” and elsewhere in Nuo’s public filings with the U.S. Securities and Exchange Commission from time to time, including Nuo’s annual report on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K. You are advised to carefully consider these various risks, uncertainties, and other factors. Nuo expressly disclaims any intent or obligation to update or revise publicly these forward-looking statements except as required by law.

Contact:
David Jorden
djorden@nuot.com 

 
NUO THERAPEUTICS, INC.
CONSOLIDATED BALANCE SHEETS
(Unaudited)
 
    September 30,
2026
    December 31,
2025
 
ASSETS                
Current assets                
Cash   $ 80,941     $ 548,946  
Accounts receivable, net     1,410,322       561,667  
Inventory, net     330,134       213,761  
Prepaid expenses and other current assets     162,667       55,509  
Total current assets     1,984,064       1,379,883  
                 
Property and equipment, net     704,903       366,315  
Operating lease right of use assets     41,238       99,464  
Total assets   $ 2,730,205     $ 1,845,662  
                 
LIABILITIES AND STOCKHOLDERS’ DEFICIT                
Current liabilities                
Accounts payable   $ 756,720     $ 436,083  
Accrued expenses     648,177       493,792  
Deferred revenue     380,730       300,000  
Current portion of notes payable     515,625       –  
Current portion of notes payable – related party     112,500       –  
Current portion of operating lease liabilities     40,756       76,410  
Total current liabilities     2,454,508       1,306,285  
                 
Deferred revenue – long term     951,826       975,000  
Notes payable     961,875       300,000  
Note payable – related party     210,500       200,000  
Non-current portion of operating lease liabilities     –       20,936  
Total liabilities     4,578,709       2,802,221  
                 
Stockholders’ deficit                
Common stock; $0.0001 par value, 100,000,000 shares authorized, 48,573,894 and 48,179,039 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively     4,857       4,818  
Additional paid-in capital     34,239,796       33,810,785  
Accumulated deficit     (36,093,157 )     (34,772,162 )
Total stockholders’ deficit     (1,848,504 )     (956,559 )
                 
Total liabilities and stockholders’ deficit   $ 2,730,205     $ 1,845,662  

NUO THERAPEUTICS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
 
    Three Months
ended
September 30,
2026
    Three Months
ended
September 30,
2025
 
Revenue                
Product sales   $ 1,779,563     $ 957,096  
Distribution fee revenue     86,562       75,000  
Total revenue     1,866,125       1,032,096  
                 
Costs of sales     673,334       406,721  
Gross profit     1,192,791       625,375  
                 
Operating expenses                
Selling, general and administrative     1,567,223       1,165,517  
Total operating expenses     1,567,223       1,165,517  
                 
Loss from operations     (374,432 )     (540,142 )
                 
Other income (expense)                
Interest income (expense), net     (51,099 )     409  
Other income     603       1,814  
Total other income (expenses)     (50,496 )     2,223  
                 
Net loss   $ (424,928 )   $ (537,919 )
                 
Loss per common share          
Basic and diluted   $ (0.01 )   $ (0.01 )
                 
Weighted average common shares outstanding          
Basic and diluted     48,472,374       47,539,384  

NUO THERAPEUTICS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
 
    Nine Months
ended
September 30,
2026
    Nine Months
ended
September 30,
2025
 
Revenue                
Product sales   $ 4,694,782     $ 2,066,679  
Distribution fee revenue     242,444       150,000  
Total revenue     4,937,226       2,216,679  
                 
Costs of sales     1,724,681       687,092  
Gross profit     3,212,545       1,529,587  
                 
Operating expenses                
Selling, general and administrative     4,199,995       3,466,898  
Total operating expenses     4,199,995       3,466,898  
                 
Loss from operations     (987,450 )     (1,937,311 )
                 
Other income (expense)                
Interest income (expense), net     (340,447 )     (33 )
Other income     6,902       3,608  
Total other income (expenses)     (333,545 )     3,575  
                 
Net loss   $ (1,320,995 )   $ (1,933,736 )
                 
Loss per common share          
Basic and diluted   $ (0.03 )   $ (0.04 )
                 
Weighted average common shares outstanding          
Basic and diluted     48,389,216       47,062,186  


Primary Logo

Media gallery

About The Author